- Home
- PMAX vs INAB Comparison
PMAX vs INAB Comparison
Compare PMAX & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMAX
- INAB
- Stock Information
- Founded
- PMAX 2019
- INAB 2016
- Country
- PMAX Hong Kong
- INAB United States
- Employees
- PMAX N/A
- INAB N/A
- Industry
- PMAX
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- PMAX
- INAB Health Care
- Exchange
- PMAX Nasdaq
- INAB Nasdaq
- Market Cap
- PMAX 6.7M
- INAB 7.5M
- IPO Year
- PMAX 2024
- INAB 2021
- Fundamental
- Price
- PMAX $0.26
- INAB $2.18
- Analyst Decision
- PMAX
- INAB Strong Buy
- Analyst Count
- PMAX 0
- INAB 2
- Target Price
- PMAX N/A
- INAB $108.00
- AVG Volume (30 Days)
- PMAX 1.9M
- INAB 58.2K
- Earning Date
- PMAX 10-17-2025
- INAB 08-07-2025
- Dividend Yield
- PMAX N/A
- INAB N/A
- EPS Growth
- PMAX N/A
- INAB N/A
- EPS
- PMAX N/A
- INAB N/A
- Revenue
- PMAX $4,694,079.00
- INAB N/A
- Revenue This Year
- PMAX N/A
- INAB N/A
- Revenue Next Year
- PMAX N/A
- INAB N/A
- P/E Ratio
- PMAX N/A
- INAB N/A
- Revenue Growth
- PMAX N/A
- INAB N/A
- 52 Week Low
- PMAX $0.23
- INAB $1.98
- 52 Week High
- PMAX $4.70
- INAB $16.70
- Technical
- Relative Strength Index (RSI)
- PMAX 31.60
- INAB 43.30
- Support Level
- PMAX $0.30
- INAB $2.18
- Resistance Level
- PMAX $0.33
- INAB $2.26
- Average True Range (ATR)
- PMAX 0.05
- INAB 0.10
- MACD
- PMAX -0.01
- INAB -0.00
- Stochastic Oscillator
- PMAX 12.43
- INAB 25.71
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.